Lilly Highlights Symbyax Onset Of Action; Other Bipolar Presentations At APA
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Lilly is highlighting a rapid onset of action and lack of treatment-emergent mania for its olanzapine/fluoxetine combination Symbyax, currently pending at FDA for the treatment of bipolar depression.